HDL X JEJUM PUBMED

(intermittent fasting) AND (HDL) ensaios clínicos / últimos 5 anos português /

inglês – artigos 394
Em português = 0 artigos
Aplicando o filtro por sexo feminino – 332 artigos
Aplicando filtro adultos 19+ – 301 artigos

Após leitura do abstract:

1 artigos mulher
4 artigos ambos

MULHERES PUBMED (1):

Effect of intermittent compared to continuous energy restriction on weight loss
and weight maintenance after 12 months in healthy overweight or obese adults
Michelle Louise Headland 1 2, Peter Marshall Clifton 1 2, Jennifer Beatrice
Keogh 3 4
Affiliations expand DOI: 10.1038/s41366-018-0247-2
Erratum in
 Correction: Effect of intermittent compared to continuous energy
restriction on weight loss and weight maintenance after 12 months in
healthy overweight or obese adults.
Headland ML, Clifton PM, Keogh JB.Int J Obes (Lond). 2019
Apr;43(4):942. doi: 10.1038/s41366-019-0339-7.PMID: 30842547

Abstract

Background and objective: Intermittent energy restriction (IER) is an

alternative to continuous energy restriction (CER) for weight loss. There are few
long-term trials comparing efficacy of these methods. The objective was to
compare the effects of CER to two forms of IER; a week-on-week-off energy
restriction and a 5:2 program, during which participants restricted their energy
intake severely for 2 days and ate as usual for 5 days, on weight loss, body
composition, blood lipids, and glucose.

Subjects and methods: A one-year randomized parallel trial was conducted at

the University of South Australia, Adelaide, Australia. Participants were 332
overweight and obese adults, ages 18-72 years, who were randomized to 1 of 3
groups: CER (4200 kJ/day for women and 5040 kJ/day for men), week-on-
week-off energy restriction (alternating between the same energy restriction as
the continuous group for one week and one week of habitual diet), or 5:2 (2100
kJ/day on modified fast days each week for women and 2520 kJ/day for men,
the 2 days of energy restriction could be consecutive or non-consecutive).
Primary outcome was weight loss, and secondary outcomes were changes in
body composition, blood lipids, and glucose.
Results: For the 146 individuals who completed the study (124 female, 22
male, mean BMI 33 kg/m2) mean weight loss, and body fat loss at 12 months
was similar in the three intervention groups, -6.6 kg for CER, -5.1 kg for the
week-on, week-off and -5.0 kg for 5:2 (p = 0.2 time by diet). Discontinuation
rates were not different (p = 0.4). HDL-cholesterol rose (7%) and triglycerides
decreased (13%) at 12 months with no differences between groups. No
changes were seen for fasting glucose or LDL-cholesterol.

Discussion and conclusion: The two forms of IER were not statistically

different for weight loss, body composition, and cardiometabolic risk factors
compared to CER.

AMBOS SEXOS PUBMED (4):

1

Effect of intermittent versus continuous energy restriction on weight loss,

maintenance and cardiometabolic risk: A randomized 1-year trial

T M Sundfør 1, M Svendsen 2, S Tonstad 2

Affiliations expand

 DOI: 10.1016/j.numecd.2018.03.009

Abstract

Background & aims: Long-term adherence to conventional weight-loss diets is

limited while intermittent fasting has risen in popularity. We compared the
effects of intermittent versus continuous energy restriction on weight loss,
maintenance and cardiometabolic risk factors in adults with abdominal obesity
and ≥1 additional component of metabolic syndrome.

Methods & results: In total 112 participants (men [50%] and women [50%])
aged 21-70 years with BMI 30-45 kg/m2 (mean 35.2 [SD 3.7]) were randomized
to intermittent or continuous energy restriction. A 6-month weight-loss phase
including 10 visits with dieticians was followed by a 6-month maintenance
phase without additional face-to-face counselling. The intermittent energy
restriction group was advised to consume 400/600 kcal (female/male) on two
non-consecutive days. Based on dietary records both groups reduced energy
intake by ∼26-28%. Weight loss was similar among participants in the
intermittent and continuous energy restriction groups (8.0 kg [SD 6.5] versus 9.0
kg [SD 7.1]; p = 0.6). There were favorable improvements in waist
circumference, blood pressure, triglycerides and HDL-cholesterol with no
difference between groups. Weight regain was minimal and similar between the
intermittent and continuous energy restriction groups (1.1 kg [SD 3.8] versus 0.4
kg [SD 4.0]; p = 0.6). Intermittent restriction participants reported higher hunger
scores than continuous restriction participants on a subjective numeric rating
scale (4.7 [SD 2.2] vs 3.6 [SD 2.2]; p = 0.002).

Conclusions: Both intermittent and continuous energy restriction resulted in

similar weight loss, maintenance and improvements in cardiovascular risk
factors after one year. However, feelings of hunger may be more pronounced
during intermittent energy restriction.

Trial registration: www.clinicaltrials.govNCT02480504.

Keywords: Cardiometabolic risk factors; Intermittent energy restriction;

Metabolic syndrome; Weight loss.

2
doi: 10.1021/acs.jproteome.9b00090. Epub 2019 Apr 1.

Proteomic Analysis of Human Plasma during Intermittent Fasting

Dylan J Harney 1, Amy T Hutchison 2, Luke Hatchwell 1, Sean J
Humphrey 1, David E James 1, Samantha Hocking 3, Leonie K Heilbronn 2, Mark
Larance 1
Affiliations expand

 DOI: 10.1021/acs.jproteome.9b00090

Free PMC article

Abstract

Intermittent fasting (IF) increases lifespan and decreases metabolic disease

phenotypes and cancer risk in model organisms, but the health benefits of IF in
humans are less clear. Human plasma derived from clinical trials is one of the
most difficult sample sets to analyze using mass spectrometry-based
proteomics due to the extensive sample preparation required and the need to
process many samples to achieve statistical significance. Here, we describe an
optimized and accessible device (Spin96) to accommodate up to 96 StageTips,
a widely used sample preparation medium enabling efficient and consistent
processing of samples prior to LC-MS/MS. We have applied this device to the
analysis of human plasma from a clinical trial of IF. In this longitudinal study
employing 8-weeks IF, we identified significant abundance differences induced
by the IF intervention, including increased apolipoprotein A4 (APOA4) and
decreased apolipoprotein C2 (APOC2) and C3 (APOC3). These changes
correlated with a significant decrease in plasma triglycerides after the IF
intervention. Given that these proteins have a role in regulating apolipoprotein
particle metabolism, we propose that IF had a positive effect on lipid
metabolism through modulation of HDL particle size and function. In addition,
we applied a novel human protein variant database to detect common protein
variants across the participants. We show that consistent detection of clinically
relevant peptides derived from both alleles of many proteins is possible,
including some that are associated with human metabolic phenotypes.
Together, these findings illustrate the power of accessible workflows for
proteomics analysis of clinical samples to yield significant biological insight.

Keywords: 3D-printing; 96-well; human; intermittent fasting; liquid

chromatography; mass spectrometry (MS); plasma; sample cleanup; solid-
phase extraction (SPE).

doi: 10.1186/s12876-019-1132-8.

Effects of alternate-day fasting on body weight and dyslipidaemia in patients

with non-alcoholic fatty liver disease: a randomised controlled trial
Hua Cai 1, Yue-Lan Qin 1, Ze-Ya Shi 1, Jin-Hui Chen 1, Min-Jie Zeng 1, Wei
Zhou 1, Ru-Qun Chen 1, Zhi-Yuan Chen 2
Affiliations expand

 DOI: 10.1186/s12876-019-1132-8

Free PMC article

Abstract

Background: Alternate-day fasting (ADF) is a novel diet therapy that may

achieve reduction in body weight and improvement of dyslipidaemia, but the
impact of this diet on patients with non-alcoholic fatty liver disease (NAFLD)
remains unknown. The aim of this study was to evaluate the effects of ADF on
the body weight and lipid profile of individuals with NAFLD.

Methods: NAFLD patients (n = 271) were randomised to the ADF group, time-

restricted feeding (TRF) group, or the control group and subjected to the
respective diet for 12 weeks. Anthropometric measurements (body weight, fat
mass/fat-free mass) were performed, and plasma lipids were analysed
enzymatically.

Results: Within 4 weeks, the body weight decreased significantly (P < 0.001) in

the ADF group by 4.56 ± 0.41 kg (6.1 ± 0.5%) and the TRF group by 3.62 ±
0.65 kg (4.83 ± 0.9%) compared to the control group, and it decreased even
more after 12 weeks in both groups (ADF: - 4.04 ± 0.54 kg, 5.4 ± 0.7%; TRF: -
3.25 ± 0.67 kg, 4.3 ± 0.9%). Fat mass was significantly reduced by ADF (- 3.49
± 0.37 kg; 11 ± 1.2%) and TRF (- 2.91 ± 0.41 kg; 9.6 ± 1.3%), with ADF leading
to a further reduction in fat mass after 12 weeks (- 3.48 ± 0.38 kg; 11 ± 1.2%).
Total cholesterol was significantly decreased at both time points in the ADF
group (- 0.91 ± 0.07 mmol/L; 18.5 ± 1.5%) compared to the control and TRF
groups. Both ADF (- 0.64 ± 0.06 mmol/L; 25 ± 1.9%) and TRF (0.58 ± 0.07
mmol/L; 20 ± 1.7%) achieved a significant reduction in serum triglycerides (P <
0.001) after 12 weeks. Changes in fat free mass, HDL, LDL, fasting insulin,
glucose, liver stiffness, and systolic or diastolic blood pressure did not differ
between the groups.

Conclusions: ADF appears to be an effective diet therapy for individuals with

NAFLD that can achieve weight loss and improvement of dyslipidaemia within a
relatively short period of time (4 to 12 weeks). Potential preventive effects of
ADF on cardiovascular disease need to be confirmed by future investigations.

doi: 10.1016/j.ctim.2019.08.021. Epub 2019 Aug 28.

Modified alternate-day fasting vs. calorie restriction in the treatment of patients

with metabolic syndrome: A randomized clinical trial
Arefe Parvaresh 1, Roghaye Razavi 1, Behnood Abbasi 2, Khadijeh
Yaghoobloo 1, Akbar Hassanzadeh 3, Noushin Mohammadifard 4, Sayyed
Morteza Safavi 5, Amir Hadi 6, Cain C T Clark 7
Affiliations expand 

 DOI: 10.1016/j.ctim.2019.08.021

Abstract

Objective: The aim of present study was to compare the effect of calorie

restriction and modified alternate-day fasting diet on treatment of adults with
metabolic syndrome.

Design: This randomized clinical trial was conducted on 70 participants

diagnosed with metabolic syndrome.

Setting: Patients were randomly allocated into 2 groups to follow either calorie

restriction or a modified alternate-day fasting diet for 8 weeks. Diets was
prescribed by dietitians and specialized for each participant. Anthropometric
parameters, blood pressure, fasting plasma glucose, fasting insulin, HOMA-IR
and lipid profile were measured at baseline and after trial conclusion.

Results: 69, out of 70, participants completed the study and were included in
the final analysis. The results showed that, compared with calorie restriction,
following the modified alternate-day fasting diet significantly reduced body
weight (P = 0.003), waist circumference (P = 0.026), systolic blood pressure (P
= 0.029) and fasting plasma glucose (P = 0.009). However, no significant
difference was observed between the 2 groups in triglyceride (P = 0.614), total
cholesterol (P = 0.759), LDL-C (P = 0.289), HDL-C (P = 0.909), diastolic blood
pressure (P = 0.262), HOMA- IR (P = 0.425) and fasting insulin concentrations
(P = 0.496). In addition, the participants did not report any complaint due to
difficulties with diet adherence when following calorie restriction or modified
alternate-day fasting diet.
Conclusions: the present study suggests that modified alternate-day fasting
diet may be a more effective option in managing body weight, waist
circumference, systolic blood pressure, and fasting plasma glucose, compared
with common calorie restriction. Further studies are needed to confirm the
veracity of our results.

Keywords: Alternate-day fasting; Anthropometric; Energy restriction; Glycemic

index; Metabolic syndrome x; Plasma lipids.

HDL X JEJUM BVS

(intermittent fasting) AND (hdl) ensaios clínicos / últimos 5
anos / português / inglês – artigos 61

Após leitura do abstract:

0 artigos Mulheres
1 artigos ambos os sexos

AMBOS SEXOS BVS (1):

Impact of Intermittent Fasting on Lipid Profile-A Quasi-Randomized Clinical

Trial. 
Ahmed, Naseer;  Farooq, Javeria;  Siddiqi, Hasan Salman;  Meo, Sultan
Ayoub;  Kulsoom, Bibi;  Laghari, Abid H;  Jamshed, Humaira; Pasha, Farooq. 
Front Nutr  ; 7: 596787, 2020. 
Artigo em Inglês | MEDLINE | ID: mdl-33598473

RESUMO
Background: Sub-optimal HDL is a prognostic marker of cardiovascular
disease. South Asia has a high prevalence of sub-optimal HDL compared to
other parts of the world. Intermittent fasting (IF) is a type of energy restriction
which may improve serum HDL and other lipids thereby reducing the risk of
cardiovascular diseases. Objective: The aim of the study was to evaluate the
effect of IF on lipid profile and HDL-cholesterol in a sample of South Asian
adults. Methods: A 6-week quasi-experimental (non-randomized) clinical trial
was conducted on participants with low HDL (< 40 mg/dl for men and < 50
mg/dl for women). Participants of the control group were recommended not to
change their diet. The intervention group was recommended to fast for ~12 h
during day time, three times per week for 6 weeks. Pulse rate, blood pressure,
body weight, waist circumference, serum lipid profile, and blood glucose levels
were measured at baseline and after 6 weeks. Result: A total of 40 participants
were enrolled in the study (N = 20 in each group), while 35 (20 control and 15
intervention) completed the trial and were included in data analysis of the study.
Body measurements, including body weight, BMI and waist circumference,
showed significant interaction effects (p's < 0.001), indicating that there were
larger reductions in the IF group than in the control group. Significant interaction
effects were also observed for total (p = 0.033), HDL (p = 0.0001), and LDL
cholesterol (p = 0.010) with larger improvements in the IF group. Conclusion:
This study suggests that intermittent fasting may protect cardiovascular health
by improving the lipid profile and raising the sub-optimal HDL. Intermittent
fasting may be adopted as a lifestyle intervention for the prevention,
management and treatment of cardiovascular disorders. Clinical Trial
Registration: NCT03805776, registered on January 16, 2019, 

HDL X JEJUM SCIELO

(intermittent fasting) AND (hdl) ensaios clínicos / últimos 5
anos / português / inglês

1.   Esquema de ayuno intermitente y reducción de medidas antropométricas, perfil

lipídico, presión arterial y riesgo cardiovascular 
 Facebook Twitter  
Wong-Gonzales, José J. Javier   ;  Quispe-Palacios, José Antonio   . 
Revista de la Facultad de Medicina Humana Jan  2022, Volume  22  Nº  1 Páginas 139 - 146
Resumo:  EN  ES | Texto: EN ES | PDF: EN | PDF: ES
https://doi.org/10.25176/rfmh.v22i1.4383

ABSTRACT

Introduction: Lifestyle is a fundamental role in the risk of cardiovascular diseases and chronic diseases.
Objective: To evaluate the effect of the 16/8 intermittent fasting scheme against anthropometric
measurements, lipid prole values, blood pressure and cardiovascular risk. Method: Longitudinal
analytical study with intervention. Fifteen patients treated in the nutrition area in a private center between
January and October 2020 submitted to the 16/8 intermittent fasting scheme for four months, seeking to
reduce anthropometric measurements, lipid prole, blood pressure and / or cardiovascular risk. Variables:
body weight, body mass index (BMI), waist-hip index (WHI), abdominal circumference, lipid prole,
cardiovascular risk according to Framingham (Framingham AMR B table), total cholesterol / HDL and
LDL / HDL indices. Results: The average age was 47.1 years, the average height was 1.66 m., The
average body weight was 84.3 Kg., The average of the BMI was 30.46, the average of the WHI was 0.94,
the average of the abdominal circumference was 99.87, the mean total cholesterol, HDL and LDL were
240.06, 43.73 and 153.2 respectively, the mean cardiovascular risk according to Framingham was 0.11%
and the mean total cholesterol / HDL and LDL / HDL indices were 5.88 and 3.69. The evaluation of
averages before and after found signicant differences (p <0.05) at 3 and 4 months of evaluation.
Conclusions: The intermittent fasting scheme showed a signicant reduction in anthropometric
measurements, lipid prole and cardiovascular risk. Additionally, an increase in HDL was observed.